Development and Validation of Therapeutically Relevant Multi-Gene Biomarker Classifiers

Simon, Richard
June 2005
JNCI: Journal of the National Cancer Institute;6/15/2005, Vol. 97 Issue 12, p866
Academic Journal
Attempts to provide possible explanations for the inconsistency of results of a June 2004 study on a two-gene expression ratio that authors claimed accurately predicted clinical outcome of early-stage breast cancer patients treated with adjuvant tamoxifen monotherapy and a 2005 study that failed to confirm the usefulness of the two-gene expression ratio. Microarray expression profiling; Method used in the first study to develop the classification model.


Related Articles

  • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi, Sherene; Haibe-Kains, Benjamin; Desmedt, Christine; Wirapati, Pratyaksha; Lallemand, Françoise; Tutt, Andrew M.; Gillet, Cheryl; Ellis, Paul; Ryder, Kenneth; Reid, James F.; Daidone, Maria G.; Pierotti, Marco A.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.; Foekens, John A.; Delorenzi, Mauro; Bontempi, Gianluca; Piccart, Martine J.; Sotiriou, Christos // BMC Genomics;2008, Vol. 9, Special section p1 

    Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen...

  • The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Egeland, Nina G.; Lunde, Siri; Jonsdottir, Kristin; Lende, Tone H.; Cronin-Fenton, Deirdre; Gilje, Bjørnar; Janssen, Emiel A. M.; Søiland, Håvard // International Journal of Molecular Sciences;2015, Vol. 16 Issue 10, p24243 

    Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological...

  • Biological determinants of endocrine resistance in breast cancer. Musgrove, Elizabeth A.; Sutherland, Robert L. // Nature Reviews Cancer;Sep2009, Vol. 9 Issue 9, p631 

    Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of...

  • PUGSVM: a caBIGTM analytical tool for multiclass gene selection and predictive classification. Yu, Guoqiang; Li, Huai; Ha, Sook; Shih, Ie−Ming; Clarke, Robert; Hoffman, Eric P.; Madhavan, Subha; Xuan, Jianhua; Wang, Yue // Bioinformatics;Mar2011, Vol. 27 Issue 5, p736 

    Summary: Phenotypic Up-regulated Gene Support Vector Machine (PUGSVM) is a cancer Biomedical Informatics Grid (caBIGâ„¢) analytical tool for multiclass gene selection and classification. PUGSVM addresses the problem of imbalanced class separability, small sample size and high gene space...

  • Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. Culhane, A. C.; Howlin, J. // Cellular & Molecular Life Sciences;Dec2007, Vol. 64 Issue 24, p3185 

    Utilisation of ‘omics’ technologies, in particular gene expression profiling, has increased dramatically in recent years. In basic research, high-throughput profiling applications are increasingly used and may now even be considered standard research tools. In the clinic, there is a...

  • Early Detection of Breast Cancer New Biomarker Tests on the Horizon? Jotwani, Aparna C.; Gralow, Julie R. // Molecular Diagnosis & Therapy;Dec2009, Vol. 13 Issue 6, p349 

    When cancer is detected early, patients live longer, require less extensive treatment, and in general fare better than patients with more advanced disease. Breast cancer is the most commonly diagnosed cancer among women. Breast cancer screening through mammography has shown significant mortality...

  • An Integrative Genomics Approach to Biomarker Discovery in Breast Cancer. Hicks, Chindo; Asfour, Rozana; Pannuti, Antonio; Miele, Lucio // Cancer Informatics;2011, Issue 9, p185 

    Genome-wide association studies (GWAS) have successfully identified genetic variants associated with risk for breast cancer. However, the molecular mechanisms through which the identified variants confer risk or influence phenotypic expression remains poorly understood. Here, we present a novel...

  • Capture and identification of proteins that bind to a GGA-rich sequence from the ERBB2 gene promoter region. Zhang, Tian; Zhang, Huiping; Wang, Yuexi; McGown, Linda // Analytical & Bioanalytical Chemistry;Dec2012, Vol. 404 Issue 6/7, p1867 

    The ERBB2 gene (HER2/neu) is overexpressed in many human breast cancers. It is an important therapeutic target and its product protein is a key biomarker for breast cancer. A 28-bp GGA repeat sequence (Pu28-mer) in the nuclease hypersensitive site of the ERBB2 promoter region may play an...

  • Predicting features of breast cancer with gene expression patterns. Xuesong Lu; Xin Lu; Wang, Zhigang C.; Iglehart, J. Dirk; Xuegong Zhang; Richardson, Andrea L. // Breast Cancer Research & Treatment;Mar2008, Vol. 108 Issue 2, p191 

    Data from gene expression arrays hold an enormous amount of biological information. We sought to determine if global gene expression in primary breast cancers contained information about biologic, histologic, and anatomic features of the disease in individual patients. Microarray data from the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics